View More Recent Stories

Aug 25, 2020 08:37PM Mesoblast 2020 Full Year Financial Results Webcast
Aug 14, 2020 06:11AM Mesoblast (MESO) Confirms U.S. FDA Advisory Committee Votes Nine to One in Favor of Remestemcel-L for Efficacy in Children With SR-aGVHD
Aug 14, 2020 06:00AM U.S. FDA Advisory Committee Votes Nine to One in Favor of Remestemcel-L (Ryoncil™) for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease
Aug 11, 2020 06:25AM Mesoblast (MESO) Announces Update on Scheduled FDA Advisory Committee Meeting
Aug 11, 2020 06:00AM Update on Scheduled FDA Advisory Committee Meeting
Jul 30, 2020 06:00AM Mesoblast Provides Remestemcel-L Update and Quarterly Activity Report
Jul 24, 2020 06:00AM Executive Leadership Expanded Ahead of First Potential U.S. Product Launch
Jul 21, 2020 05:33PM Mesoblast Limited (MESO) Announces FDA Advisory Committee Sets Review Date for its remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease
Jul 21, 2020 05:32PM FDA Advisory Committee Sets Review Date for Mesoblast’s remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease
Jul 6, 2020 06:00AM Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19
Jun 1, 2020 06:00AM Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease
May 27, 2020 05:52PM Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020
May 26, 2020 06:00AM Mesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020
May 25, 2020 07:00AM Clinical Outcomes Using RYONCIL™ (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow Transplantation
May 13, 2020 06:00AM Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS
May 6, 2020 06:24AM Mesoblast (MESO) Reports First Patient Dosed in Phase 2/3 Randomized Controlled Trial of Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
May 6, 2020 06:00AM First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Apr 30, 2020 07:00AM Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment
Apr 24, 2020 07:43AM Mesoblast Limited (MESO) Reports 83% survival in ventilator-dependent COVID-19 patients
Apr 24, 2020 06:00AM 83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L
Apr 17, 2020 06:00AM Mesoblast to Present Positive Clinical Outcomes Using Remestemcel-L in Patients With Inflammatory Lung Disease at 2020 International Society of Cell and Gene Therapy Annual Meeting
Apr 8, 2020 07:15PM MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED T
Apr 6, 2020 06:07AM Mesoblast (MESO) Granted FDA Clearance NDA to Use Remestemcel-L in Patients with Acute Respiratory Distress Syndrome Caused by COVID-19
Apr 6, 2020 06:00AM FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19
Apr 1, 2020 06:00AM FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW
Mar 30, 2020 06:00AM CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS
Mar 10, 2020 06:00AM Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease
Feb 26, 2020 04:59PM Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019
Feb 25, 2020 06:00AM Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019
Feb 24, 2020 06:00AM Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD
Feb 20, 2020 06:00AM Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease
Feb 3, 2020 06:00AM Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA
Feb 3, 2020 06:00AM Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA
Jan 15, 2020 06:00AM Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco
Jan 2, 2020 06:00AM Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L
Dec 18, 2019 06:00AM Data Monitoring Committee Completes Final Scheduled Review of Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure
Dec 17, 2019 06:00AM Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion
Nov 25, 2019 04:52PM Mesoblast Finanical Results for the Quarter Ended September 30, 2019
Nov 21, 2019 04:29PM Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019
Oct 16, 2019 06:17PM Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
Oct 3, 2019 07:59AM Mesoblast Completes Successful Institutional Capital Raising of A$75 Million
View More Recent Stories